Cat's claw Uncaria tomentosa (Willd. ex Schult.) DC.
Also called: uña de gato, saventaro, life-giving vine of Peru
Cat's claw is a woody vine of the Amazon rainforest and other tropical areas of Central and South America, named for its hooked thorns. Supplements use the bark; most US products contain Uncaria tomentosa rather than the related Uncaria guianensis.
- Category
- Botanical
- Part used
- Bark (stem bark or root bark; many studies do not state which)
- Strongest evidence
- C Limited
- Native range
- Native to Central and tropical South America to Trinidad (POWO: "Central & S. Tropical America to Trinidad")
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. No review stating a count was found. This entry cites 4 RCTs of Uncaria tomentosa bark extracts alone: sources 5 and 11-13, versus placebo or chemotherapy alone, 12 to 43 participants. Source 6 tested another species, U. guianensis. [5]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CCancer1 topic
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Rheumatoid arthritis (adults also taking sulfasalazine or hydroxychloroquine) | C | A 24-week placebo-controlled trial in 40 patients found fewer painful joints with a pentacyclic-chemotype extract (53.2% vs 24.1% reduction); the authors called it a small preliminary study. [5] |
| Knee osteoarthritis (Uncaria guianensis) | C | A 4-week trial in 45 patients (30 freeze-dried U. guianensis, 15 placebo) reported less pain with activity; knee pain at rest or at night did not change significantly. [6] |
| Quality of life in advanced cancer | C | A prospective phase II study (no comparison group described) in 51 patients with advanced solid tumors (100 mg dry extract three times daily) reported improved quality-of-life and fatigue scores; no tumor responses were detected. [7] |
| Any health use (overall) | C | NCCIH: very few high-quality trials exist, and no conclusive evidence from human studies supports cat's claw for any health purpose, including COVID-19. [1] |
Main constituents: Oxindole alkaloids, in two chemotypes: one mainly pentacyclic (e.g., pteropodine, mitraphylline), one mainly tetracyclic (e.g., rhynchophylline) [3]; Pyroquinovic acid glycosides, described as markers of the species [3]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 100 mg of a dry extract three times daily in a phase II study in patients with advanced solid tumors. [7]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
LiverTox (chapter dated February 18, 2019): cat's claw has not been implicated in causing liver injury.
Details and sources - Pregnancy and breastfeedingNCCIH: some studies of use during pregnancy suggest it is unsafe; little is known about breastfeeding.
2 statements in the profile.
Details and sources - Interactions with medicines4 listed
HIV protease inhibitors (atazanavir, ritonavir, saquinavir); CYP3A4 substrates; UGT1A3 and UGT1A9 substrates …
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Appears to be safe when taken by mouth for short periods, as much as 6 months; there is insufficient reliable information on safety when applied to the skin. [1]
- Might make the immune system more active, which could increase symptoms of autoimmune diseases; may slow blood clotting and increase bleeding risk during surgery. [1]
- Some studies of use during pregnancy suggest it is unsafe; little is known about safety during breastfeeding. [1]
- LiverTox: cat's claw has not been implicated in causing liver injury. [8]
- Reported side effects: nausea, diarrhea, stomach discomfort. Case reports: acute kidney failure in a patient with lupus, and worsening of motor signs in a patient with Parkinson's disease. [2]
Interactions
| With | What happens |
|---|---|
| HIV protease inhibitors (atazanavir, ritonavir, saquinavir) | In a case report, trough levels of all three were raised during cat's claw use and returned toward normal 15 days after it was stopped. [3] |
| Anticoagulants and blood pressure drugs | May increase the effects of these drugs, including bleeding risk; clinical relevance is not known. [2] |
| CYP3A4 substrates | Cat's claw inhibits CYP3A4 in vitro and may raise levels of drugs such as non-nucleoside reverse-transcriptase inhibitors, cyclosporine and some benzodiazepines; clinical relevance is not known. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- USP (as cited by EMA) defines cat's claw as the inner stem bark with at least 0.3% pentacyclic oxindole alkaloids and no more than 0.05% tetracyclic alkaloids. [3]
- Alkaloid content can vary 10- to 40-fold with cultivation and harvest season; the more easily found Uncaria guianensis is a common adulterant, and the names cat's claw and uña de gato are used for several tropical American plants. [3]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements before they are marketed; firms are responsible for the safety and labeling of their products. [10]
- EU: the HMPC concluded in 2015 that an EU herbal monograph cannot be established; stem-bark preparations had been in EU medicinal use for more than 15 but less than 30 years. [4]
- EU: EMA's assessment found well-established use not acceptable in any investigated condition; 12 small trials had studied 7 different effects with different extracts. [3]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Oxindole alkaloids (pentacyclic and tetracyclic chemotypes) Alkaloids (oxindole alkaloids) [P4]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming cat's claw (Uncaria tomentosa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC classification of cat's claw (Uncaria tomentosa) was found in the IARC Monographs list of classifications (Volumes 1–142, list updated 2026-07-23; checked 2026-10-29). [P2]
- No NTP technical report (2-year study) on cat's claw (Uncaria tomentosa) was found in NTP's list of technical reports (checked 2026-10-29). [P8]
Liver (NIH LiverTox)
- LiverTox (chapter dated February 18, 2019): cat's claw has not been implicated in causing liver injury. [P3]
Interactions with medicines
- HIV protease inhibitors (atazanavir, ritonavir, saquinavir): Case report: trough levels of all three were raised during cat's claw use and returned toward normal 15 days after it was stopped. [P4]
- CYP3A4 substrates: Inhibits CYP3A4 in vitro; may raise levels of non-nucleoside reverse-transcriptase inhibitors, cyclosporine and some benzodiazepines. Clinical relevance not known. [P5]
- UGT1A3 and UGT1A9 substrates: A cat's claw extract induced UGT1A3 and 1A9 and may alter the effect of drugs metabolized by these enzymes. Clinical relevance not known. [P5]
- Anticoagulants, antiplatelet and blood pressure drugs: NCCIH: there are theoretical reasons to suspect that cat's claw might interact with anticoagulant, antiplatelet and blood pressure drugs. [P6]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- EMA (2015): overharvesting has reduced Uncaria tomentosa in Peruvian rainforests, and the lower-growing, easier-to-find Uncaria guianensis is a common adulterant in cat's claw products. [P4]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) unless FDA grants an exemption petition under 111.75(a)(1)(ii) [P7]
- Oxindole alkaloid profile (pentacyclic and tetracyclic content) — USP limits (at least 0.3% pentacyclic, no more than 0.05% tetracyclic); two chemotypes differ greatly in alkaloid pattern [P4]
- Species identity versus Uncaria guianensis — U. guianensis reported as a common adulterant [P4]
Supply and conservation
- EMA (2015) reports that Uncaria tomentosa has declined in Peruvian rainforests through overharvesting. [P4]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- LiverTox (NIDDK). Cat's Claw. Chapter dated February 18, 2019 (PMID 31643645), 2019-02-18. pubmed.ncbi.nlm.nih.gov
- EMA, HMPC. Assessment report on Uncaria tomentosa (Willd. ex Schult.) DC., cortex. EMA/HMPC/259598/2014 (24 November 2015), 2015-11-24. ema.europa.eu
- Memorial Sloan Kettering Cancer Center. About Herbs: Cat's Claw (last updated July 5, 2022), 2022-07-05. mskcc.org
- NCCIH. Cat's Claw (last updated November 2024), 2024-11. nccih.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- National Toxicology Program. Technical Reports (list of TR studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources
- NCCIH. Cat's Claw (last updated November 2024), 2024-11. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Cat's Claw (last updated July 5, 2022), 2022-07-05. mskcc.org
- EMA, HMPC. Assessment report on Uncaria tomentosa (Willd. ex Schult.) DC., cortex. EMA/HMPC/259598/2014 (24 November 2015), 2015-11-24. ema.europa.eu
- EMA, HMPC. Public statement on Uncaria tomentosa (Willd. ex Schult.) DC., cortex. EMA/HMPC/588732/2014 (24 November 2015), 2015-11-24. ema.europa.eu
- Mur E, et al. Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol 2002;29(4):678-81 (PMID 11950006), 2002-04. pubmed.ncbi.nlm.nih.gov
- Piscoya J, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001;50(9):442-8 (PMID 11603848), 2001-09. pubmed.ncbi.nlm.nih.gov
- de Paula LC, et al. Uncaria tomentosa (cat's claw) improves quality of life in patients with advanced solid tumors. J Altern Complement Med 2015;21(1):22-30 (PMID 25495394), 2015-01. pubmed.ncbi.nlm.nih.gov
- LiverTox (NIDDK). Cat's Claw. Chapter dated February 18, 2019 (PMID 31643645), 2019-02-18. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Uncaria tomentosa (Willd. ex Schult.) DC. (accessed 2026-10-29; native range: "Central & S. Tropical America to Trinidad"), 2026-10-29. powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Sheng Y, et al. DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study. Phytomedicine 2001;8(4):275-82 (PMID 11515717), 2001-07. pubmed.ncbi.nlm.nih.gov
- Farias IL, et al. Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial. Evid Based Complement Alternat Med 2012;2012:892182 (PMID 21869902), 2011-08-21. pubmed.ncbi.nlm.nih.gov
- Santos Araújo Mdo C, et al. Uncaria tomentosa-Adjuvant Treatment for Breast Cancer: Clinical Trial. Evid Based Complement Alternat Med 2012;2012:676984 (PMID 22811748), 2012-06-28. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.